UBS initiates Ensysce Biosciences stock with buy on pain therapy potential

🌐 Investing.com (Cyprus) — 2026-11-12

UBS initiated coverage of Ensysce Biosciences with a buy rating, citing the potential of its pain-therapy pipeline. The headline does not provide further details on the company or the therapy.

Markets Health UBS Ensysce Biosciences stock rating pain therapy biotechnology

Read original source →

The Most Likely Aircraft To Replace The Airbus A380 On High-Capacity Routes
Simple Flying Aviation — 2026-11-12
Romanian government plans to dissolve or merge over 100 state entities, Social Democratic leader says
Romania Insider — 2026-11-12
Merz urges EU to stand firm on carbon market reforms despite growing opposition
Euronews — 2026-11-12
[READOUT] As Q3 GDP slows to 2.1%, what are businesses seeing?
Rappler — 2026-11-12
United Utilities H1 FY27 slides: capex guidance raised, 9.5% asset growth
Investing.com — 2026-11-12
Siemens FY26 slides: industrial AI drives record orders, raised targets
Investing.com — 2026-11-12

UBS initiates Ensysce Biosciences stock with buy on pain therapy potential

AI Summary

Related Articles

The Most Likely Aircraft To Replace The Airbus A380 On High-Capacity Routes

Romanian government plans to dissolve or merge over 100 state entities, Social Democratic leader says

Merz urges EU to stand firm on carbon market reforms despite growing opposition

[READOUT] As Q3 GDP slows to 2.1%, what are businesses seeing?

United Utilities H1 FY27 slides: capex guidance raised, 9.5% asset growth

Siemens FY26 slides: industrial AI drives record orders, raised targets